Romero A, Palacín C, Mosesso P, Hodson-Walker G, Marcos R, Batiste-Alentorn M, Villamayor F, Sacristán A, Ortiz J A
Research Centre, Ferrer Group, Barcelona, Spain.
Arzneimittelforschung. 1992 May;42(5A):743-5.
A series of 6 studies has been performed to evaluate the potential genotoxic effect of 7-chloro-3-[1-(2,4-dichlorophenyl)-2-(1H- imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene (sertaconazole, FI 7045, CAS 99592-32-2). From these studies, the reverse mutation assay on Salmonella typhimurium, sex-linked recessive lethal mutations on Drosophila and genetic mutations in cultured mammal cells allowed to study the genetic mutations in prokaryotes and eukaryotes. In vitro and in vivo chromosomal aberrations were studied using human lymphocytes cytogenetic test, micronucleus test and sister chromatid exchange test. The results obtained in these studies, which are complemented one another, demonstrated that sertaconazole did not induce any signs of promutagenic, mutagenic or clastogenic activity or interference with the chromosomal segregation process.
已经开展了一系列6项研究,以评估7-氯-3-[1-(2,4-二氯苯基)-2-(1H-咪唑-1-基)乙氧基甲基]苯并[b]噻吩(舍他康唑,FI 7045,CAS 99592-32-2)的潜在遗传毒性作用。通过这些研究,利用鼠伤寒沙门氏菌的回复突变试验、果蝇的性连锁隐性致死突变试验以及培养哺乳动物细胞中的基因突变试验,得以研究原核生物和真核生物中的基因突变。使用人类淋巴细胞细胞遗传学试验、微核试验和姐妹染色单体交换试验研究了体外和体内的染色体畸变。这些相互补充的研究结果表明,舍他康唑未诱导任何促突变、诱变或致断裂活性迹象,也未干扰染色体分离过程。